In this informative panel discussion, regulatory experts and representatives from Notified Bodies discuss how companies should respond to the proposed extended transition period and start implementing the new regulatory framework to meet the MDR’s robust requirements.

This session reviews the strategic questions R&D leaders must ask before every project and highlights how they should blend technology advancement with regulatory, payment and procedure changes in their portfolio decisions.